Affibody Ab

General Electric Company

Swedish Orphan Biovitrum Ab (publ)

Ipc Research, LLC

Swedish Orphan Biovitrum Ab

Elin Gunneriusson

Malin Lindborg

Joachim Feldwisch

Fredrik Frejd

Faisal Ahmed Syud

Lars B Abrahmsen

Christofer Lendel

Brian Duh-Lan Lee

Rong Zhang

Patrik Strömberg

Paul Schaffer

Caroline Ekblad

Charlotta Berghard

Magnus Berglund

Nina Herne

Peter Brian Iveson

John Löfblom

Torbjörn Gräslund

Tove Simonsson

Johan Seijsing

Lars Abrahmsén

Michael Ernest Marino

Stefan Ståhl

Ingmarie Höidén-Guthenberg

Fredrik Nilsson

Sophia Hober

Jason William Castle

Tove Eriksson

Lindvi Gudmundsdotter

Susanne Klint

Jörgen Carlsson

Per-Åke Nygren

Elisabet Wahlberg

Per-Ake Nygren

Feifan Yu

Sarah Lindbo

Christopher Lendel

John Löblom

Nina Kronqvist

Lars ABRAHMSÉN

The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected from i) EXXXA XXEID XLPNL XXXQW XAFIXXLXD, and ii) an amino acid sequence which has at least 86% identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatment.

Polypeptides binding to human complement C5

Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.

HER2 binders

The disclosure provides a population of polypeptide variants based on a common scaffold, each polypeptide in the population comprising the scaffold amino acid sequence XAELDXXGVG AXXIKXIXXA XXVEXVQXXK QXILAX. The disclosure also provides methods for selecting and identifying polypeptides from the population, as well as such polypeptides themselves.

Polypeptides based on a scaffold

The present disclosure relates to a class of engineered polypeptides having a binding affinity for programmed death-ligand 1 (PD-L1), and provides a PD-L1 binding polypeptide comprising the sequence ERNXAAXEIL XLPNLXXXQXWAFIWXLXD. The present disclosure also relates to the use of such a PD-L1 binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.

Polypeptide

Imaging agents comprising an isolated polypeptide conjugated with a radionuclide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.

The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-6, and provides an IL-6 binding polypeptide comprising the sequence EEXXAWXEIH XLPNLXXXQXXAFIXXLXX. The present disclosure also relates to the use of such an IL-6 binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.

The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EXXXAXXEIRWLPNL XXXQRXAFIXXLXX. The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.

Polypeptides

The present disclosure relates to dimers of engineered polypeptides having a binding affinity for the neonatal Fc receptor FcRn, and provides an FcRn binding dimer, comprising a first monomer unit, a second monomer unit and an amino acid linker, wherein the first and second monomer units each comprises an FcRn binding motif. The FcRn binding dimer binds FcRn with higher capacity compared to the first monomer unit or second monomer unit alone. The present disclosure also relates to the use of the FcRn binding dimer as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.

Neonatal Fc receptor binding dimer and methods of use

The disclosure provides a HER3 binding polypeptide, comprising a HER3 binding motif, BM, which motif consists of the amino acid sequence selected from i) EXXXA XXEIW XLPNL XXXQXXAFIXXLXD, and ii) an amino acid sequence which has at least 90% identity to the sequence defined in i), wherein the polypeptide binds to the extra-cellular domain of HER3. Also provided is a bispecific ligand having binding affinity for HER3 and for HER2, or for HER3 and for EGFR, and comprising a HER3. binding polypeptide as defined herein and a HER2 binding polypeptide or a EGFR binding polypeptide.

HER3 binding polypeptides

The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EXXXAXXEIRWLPNL XXXQRXAFIXXLXX(SEQ ID NO: 1075). The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.

The present disclosure relates to a class of engineered polypeptides having a binding affinity for carbonic anhydrase IX (CAIX), and provides a CAIX binding polypeptide comprising the sequence  The present disclosure also relates to the use of such a CAIX binding polypeptide as a diagnostic, prognostic agent and/or therapeutic agent.

The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected from i) EXXXA XXEID XLPNL XXXQW XAFIXXLXD, and ii) an amino acid sequence which has at least 86% identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatments.

Growing community of inventors

Saltsjöbaden, Sweden

Elin Gunneriusson